Abstract
The European Organisation for Research and Treatment of Cancer (EORTC) is an international association under Belgian law. It was established as a cancer research organisation in 1962 by the eminent Belgian cancer expert Professor Henri Tagnon (formerly head of the Institut Bordet, the cancer center of the Free University of Brussels-Belgium) and other leading European oncologists working in the main cancer research institutes and hospitals. It was initially called `Groupe Européen de Chimiothérapie Anticancéreuse (GECA) and became the European Organisation for Research and Treatment of Cancer (EORTC) in 1968. The main reason to join forces at that time was the perceived need to conduct large-scale clinical studies which were beyond the capacity of individual centers and even national organisations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Dieras V., Chevallier B., Kerbrat P.; et al. A multicenter phase II study of docetaxel 75 mg/m2as first line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organisation for Research and Treatment of Cancer. Br. J. Cancer. 1996 Aug; 74(4): 650–6.
Fumoleau P., Chevallier B., Kerbrat P., et al. A multicenter phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann. Oncol. 1996 Feb;7(2):165–71.
Chevallier B., Fumoleau P., Kerbrat P., et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organisation for Research and Treatment of Cancer. J; Clin. Oncol. 195 Feb; 13(2)314–322.
Lhomme C., Fumoleau P., Fargeot P., et al. Results of a European Organisation for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J.Clin. Oncol. 1999 Oct;17(10):310–42.
Wagener D.J.Th., Verdonk H.E.R., Dirix L.Y., Catimel G., Siegenthaler P., Buitenhuis M., MathieuBoué A. and Verweij J. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC Early Clinical Trials Group study. Ann. Oncol. 6: 129–132, 1995.
Creemers G.J., Wanders J., Calabresi F., Valentin S., Dirix L.Y., Schöftksi P., Franklin H., McDonald M., and Verweij J. Topotecan in colorectal cancer: a phase II study of the EORTC Early Clinical Trials Group. Ann. Oncol. 6:844–846,1995
Garattini S., Bertele V. Efficacy, Safety and Costs of New Cancer drugs, BMJ, vol 325, 3 Aug 2002, 269–271.
Crott R., Neymark N. (editors). Economics of Cancer, Special Issue, EJC, Sept 2001, vol 37, No 14.,1729–1804.
Years of Excellence in Developing New Standards of Cancer Care, EJC Supplement, March 2002, vol 38, Suppl 1.,51–178. For more information on EORTC; website:http://www.eortc.be
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lacombe, D., Crott, R., Meunier, F. (2003). EORTC Research and Development: Achievements and Future Perspectives. In: Llombart-Bosch, A., Felipo, V. (eds) New Trends in Cancer for the 21st Century. Advances in Experimental Medicine and Biology, vol 532. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0081-0_22
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0081-0_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4914-3
Online ISBN: 978-1-4615-0081-0
eBook Packages: Springer Book Archive